Immix Biopharma price to book ratio IMMX
Market value divided by the book value of the company's net assets, since 2022.
- Today, Nov 2, 2026
- 2.3×
- 5-year median
- 3.2×
- Against its 5-year history
- 34th
- percentile: 0 is its lowest day, 100 its highest
- 5-year range
- 0.7× to 40.6×
- Peer median
- 2.0×
Immix Biopharma's price to book ratio is 2.3× as of Nov 2, 2026.
That is below its 5-year median of 3.2×, lower than on 66% of days in the last 5 years.
Over that time it ranged from 0.7× in Nov 2022 to 40.6× in Mar 2026.
The median for 10 large drugmakers of a similar size is 2.0×.
Price to book ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 2.3× | 2.3× | 40.6× |
| 2025 | 22.9× | 2.4× | 28.7× |
| 2024 | 3.5× | 1.7× | 6.3× |
| 2023 | 7.0× | 1.5× | 7.3× |
| 2022 | 1.9× | 0.7× | 1.9× |
Against its peers
Companies in Drug Manufacturers - General nearest Immix Biopharma's size, closest first, today.
| Company | Price to book ratio |
|---|---|
| IMMXImmix Biopharma | 2.3× |
| PBYIPuma Biotechnology | 3.8× |
| ARVNArvinas | 0.9× |
| IRWDIronwood Pharmaceuticals | n/m |
| ZVRAZevra Therapeutics | 2.8× |
| CRMDCorMedix | 0.9× |
| COLLCollegium Pharmaceutical | 2.5× |
| ABUSArbutus Biopharma | 3.1× |
| AMPHAmphastar Pharmaceuticals | 1.5× |
| NATRNatures Sunshine Products | 1.2× |
| OMEROmeros | n/m |
| Peer median | 2.0× |
What the price to book ratio tells you
Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.
Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.
More on Immix Biopharma
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.